Develops precision protein-bacteriocin antibiotics against antimicrobial resistance.
| Date | Round | Amount |
|---|---|---|
| Nov 2023 | Seed Glasgow-based Glox Therapeutics raised a GBP4.3M seed led by Boehringer Ingelheim Venture Fund and Scottish Enterprise to develop precision antibiotics. | $4.9M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.